Related references
Note: Only part of the references are listed.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting pathological B cell receptor signalling in lymphoid malignancies
Ryan M. Young et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
Wyndham H. Wilson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out
Kevin W. McCool et al.
IMMUNOLOGICAL REVIEWS (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
J. Hoellenriegel et al.
LEUKEMIA (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-kappa B Signaling Pathway
Esther P. Jane et al.
MOLECULAR CANCER THERAPEUTICS (2011)
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey J. Wallin et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Systematic exploration of synergistic drug pairs
Murat Cokol et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing
Ben G. Small et al.
NATURE CHEMICAL BIOLOGY (2011)
Critical role of PI3K signaling for NF-κB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells
Bernhard Kloo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action
Susanne C. Miller et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models
Rachele Alzani et al.
EXPERIMENTAL HEMATOLOGY (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
Shivanni Kummar et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Oncogenic Activation of NF-kappa B
Louis M. Staudt
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Joseph Lehar et al.
NATURE BIOTECHNOLOGY (2009)
Everolimus
Michael B. Atkins et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
BLOOD (2008)
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
Lloyd T. Lam et al.
BLOOD (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Combination chemical genetics
Joseph Lehar et al.
NATURE CHEMICAL BIOLOGY (2008)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Georg Lenz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
Georg Lenz et al.
SCIENCE (2008)
Withaferin A strongly elicits IκB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity
Mary Kaileh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Chemical combination effects predict connectivity in biological systems
Joseph Lehar et al.
MOLECULAR SYSTEMS BIOLOGY (2007)
Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179
Rehan Ahmad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IκB kinase (IKK)
Guoliang Qing et al.
CELL RESEARCH (2006)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles
Y Grabovsky et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Systematic discovery of multicomponent therapeutics
AA Borisy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Gene expression profiling of diffuse large B-cell lymphoma
A Rosenwald et al.
LEUKEMIA & LYMPHOMA (2003)
Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
RE Davis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
